Literature DB >> 1511316

Effects of combined methysergide and mecamylamine/scopolamine treatment on spatial navigation.

M Riekkinen1, P Riekkinen, J Sirviö, P Riekkinen.   

Abstract

In the present study, we investigated the effects of a 5-HT2 receptor antagonist, methysergide (2.5, 7.5 and 20 mg/kg), on spatial learning in saline, mecamylamine (10 mg/kg) and scopolamine (0.8 mg/kg) treated rats. Methysergide had no effect on water-maze (WM) spatial learning in rats subjected to saline or mecamylamine pretreatments. However, scopolamine-induced WM learning deficit was augmented by methysergide at doses of 7.5 and 20 mg/kg. These results further suggest (A) that cholinergic and serotonergic systems may interact in the regulation of spatial learning, and (B) that the cholinergic component of this interaction with serotonin2 receptors is mediated by muscarinic receptors, but not by nicotinic receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511316     DOI: 10.1016/0006-8993(92)91229-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.

Authors:  M Diez-Ariza; C Redondo; M García-Alloza; B Lasheras; J Del Río; M J Ramírez
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

2.  Combined treatment with a 5HT1A receptor agonist and a muscarinic acetylcholine receptor antagonist disrupts water maze navigation behavior.

Authors:  M Riekkinen; J Sirviö; T Toivanen; P Riekkinen
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

3.  Systemic injection of nicotinic acetylcholine receptor antagonist mecamylamine affects licking, eyelid size, and locomotor and autonomic activities but not temporal prediction in male mice.

Authors:  Shohei Kaneko; Koji Toda; Yasuyuki Niki; Kota Yamada; Daiki Nasukawa; Yusuke Ujihara
Journal:  Mol Brain       Date:  2022-09-06       Impact factor: 4.399

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.